Table 1.
Patients’ characteristics.
| Total | No mutations | All mutations | |||
|---|---|---|---|---|---|
| ASXL1 mutations | Other mutations | ||||
| Age at diagnosis (years) | |||||
| Median (range) | 52 (18–79) | 52 (18–79) | 54 (19–78) | 47 (24–68) | 56 (19–78) |
| Sex (n, %) | |||||
| Male | 140 (63%) | 108 (64%) | 32 (60%) | 15 (75%) | 17 (52%) |
| Female | 82 (37%) | 61 (36%) | 21 (40%) | 5 (25%) | 16 (48%) |
| EUTOS score (n, %) | |||||
| Low risk | 203 (91%) | 157 (93%) | 46 (87%) | 13 (65%) | 33 (100%) |
| High risk | 19 (9%) | 12 (7%) | 7 (13%) | 7 (35%) | 0 (0%) |
| BCR::ABL1 transcript type (n, %) | |||||
| b2a2 | 86 (39%) | 69 (41%) | 17 (32%) | 5 (25%) | 12 (36%) |
| b3a2 | 100 (45%) | 72 (43%) | 28 (53%) | 11 (55%) | 17 (52%) |
| b2a2 + b3a2 | 36 (16%) | 28 (17%) | 8 (15%) | 4 (20%) | 4 (12%) |
| Total | 222 | 169 | 53 | 20 | 33 |
EUTOS European Treatment and Outcome Study.